Codexis, Inc. · NASDAQ:CDXS
Codexis — FY2019 Earnings Presentation
10 slides from Codexis's earnings presentation, Feb 27, 2020
Slide 1: Investor Call 4Q'19 and FY'19 Results; 2020 Guidance and Outlook
Unlock the power of proteins TM February 27, 2020 Investor Call 4Q’19 and FY’19 Results; 2020 Guidance and Outlook Nasdaq: CDXS
Slide 2: Forward-Looking Statements
Forward-Looking Statements • These slides and the accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and
Slide 3: 2019: Execution on Wide Range of Strategic Objectives
2019: Execution on Wide Range of Strategic Objectives Performance Enzymes: For Pharmaceutical Manufacturing $53.9m $68.5m $58.2m • Novartis – becomes our third CodeEvolver® platform licensee • Commercializations: drug approvals at Kyorin and Allergan; NDA filing at Urovant 2019 Total Revenues Perfor
Slide 4: Select FY 2019 P&L and Balance Sheet Info
Select FY 2019 P&L and Balance Sheet Info ($ millions) For the Year Ended P&L 2019 2018 % change Total revenues 68.5 60.6 13% Product revenues 29.5 25.6 15% R&D revenues 39.0 35.0 11% Gross margin % on product revenues 47% 51% -8% Total operating expenses (R&D + SG&A) 65.4 59.3 10% GAAP net income/(
Slide 5: Selected Segment P&L Results - 2019
Selected Segment P&L Results - 2019 ($ millions) ($ millions) $68.5m $39.5mFor the Year Ended For the Year Ended Performance Enzymes Segment 2019 2018 % change Biotherapeutics Segment 2019 2018 % change Revenues: Revenues: Product revenues 29.5 25.6 15% Product revenues - - - R&D revenues 28.7 21.5
Slide 6: Codexis 2020 Financial Outlook – Continued Solid Growth
Codexis 2020 Financial Outlook – Continued Solid Growth Total Revenue ($ million) 2020 Annual Guidance Introduced $90.0 Total Revenues: $78 - 82m $82.0 $80.0 $78.0 Product Sales: $25 - 27m $70.0 $68.5 Product Gross Margin: 43% - 47% $60.6 $60.0 $50.0 $50.0 $48.8 $41.8 Additional Insights Into 2020 F
Slide 7: Performance Enzymes: Business Momentum Scorecard
Performance Enzymes: Business Momentum Scorecard Performance Enzymes Momentum Metrics 2016 2019 CAGR % Performance Enzymes Total Revenues ($m) * $44.8 $58.2 9% Product Revenues ($m) $15.3 $29.5 24% Sustaining revenues more R&D Sustaining Revenues: Royalties & CE Deal Backends ($m) -- $4.0 + + than d
Slide 8: Novel Biotherapeutics: Pipeline Progress Accelerates in 2019
Novel Biotherapeutics: Pipeline Progress Accelerates in 2019 CodeEvolver®-generated in vitro Preclinical Research IND Enabling Clinical Trials Candidate Discovery Took over asset; CDX--61146114: for Inborn PKU Error of Amino Acid Metabolism (IEAAM) - PKU Starts patient trials Co-funding Development
Slide 9: 2020 Strategic Objectives: Continued Acceleration on Multiple Fronts
2020 Strategic Objectives: Continued Acceleration on Multiple Fronts Drive Novel Biotherapeutics To Deliver Strongest Segment Revenue Growth in 2020 ✓ Advance CDX-7108 towards IND and early human trials in 1H’21 in partnership with Nestlé Health Science ✓ Discover new lead compounds and advance into
Slide 10: Thank you
Thank you February 27, 2020 Investor Call 10